DPP4 and metabolic syndrome: Research suggests that GLP-1 may have beneficial effects on dyslipidemia, and recent small studies with DPP-4 inhibitors have shown favorable effects [24,25] or a neutral effect [26] on postprandial dyslipidemia in patients with T2DM.